Back to search results

Engage for Late-Life Depression and Executive Dysfunction

This study is testing a behavioral therapy called Engage for older adults (age 60 and above) who have depression and some cognitive decline (mild cognitive impairment). Engage is a 9-week psychotherapy treatment. Researchers want to see if Engage is a good treatment option for this group of people, especially since cognitive decline can sometimes make traditional therapies harder. To join, you need to be at least 60, speak English, live near Las Vegas, and have symptoms of depression and mild cognitive impairment. The study will measure changes in your depression symptoms using a scale called the Hamilton Depression Rating Scale.

Study design
This is an interventional study with a planned enrollment of 20 participants. The study is testing a behavioral intervention called Engage.
What's involved
You would participate in a 9-week behavioral psychotherapy treatment. You would also need to travel to the UNLV campus for regular study visits.
Compensation
Not stated in the trial record.
Follow-up
Your depression symptoms will be assessed at baseline, week 6, week 9, and at a 36-week follow-up.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05356611

Engage for Late-Life Depression and Comorbid Executive Dysfunction

UNKNOWN
NAAges 60+InterventionalTreatment
University of Nevada, Las Vegas
~20 participants
Updated 2024-08-06 on ClinicalTrials.gov
What's tested:Engage

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Hamilton Depression Rating Scale
Measured over Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up.

Conditions

Depression in Old Age
Psychotherapy
Mild Cognitive Impairment
Executive Dysfunction

Explore related trials

DepressionMild cognitive disorder

NCT05356611

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Nevada

    Las Vegas, Nevadastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Brenna R Renn, PhD
[email protected]
7028950596
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 60 or older
Ability to read, write, and speak English
Located in Las Vegas or surrounding area
Ability to travel to UNLV campus by self or possible caregiver for regular study visits
Clinically significant symptoms of depression as evidenced by: 1) Scores \> 5 on the Geriatric Depression Scale-Short Form (GDS-SF)
Mild cognitive impairment as evidenced by: 1) Scores \> 18 and \< 25 on the Montreal Cognitive Assessment (MoCA)

Exclusion

Active suicidal ideation
History of suicide attempt(s)
Current symptoms of: 1) Psychosis; 2) Active substance use disorder
Reported history of: 1) Bipolar disorder ("manic depression"); 2) Intellectual disability
Currently in or scheduled to initiate individual psychotherapy to avoid treatment interference
Psychotropic medication permitted if dose was stable over the past 2 weeks
Currently living in an institutional setting (e.g., assisted living, inpatient, skilled nursing)
Presence of notable memory-specific cognitive deficits as evidenced by: scores \< 9 on the MoCA memory subscale (rendering it difficult to participate in and track/recall events for weekly psychotherapy)

What this trial measures

  • Hamilton Depression Rating ScaleAssessed at Baseline, Week 6, Week 9, and Week 36 follow-up.

    Measure of depressive symptoms used to assess changes across treatment from baseline to mid-treatment, to post-treatment, and follow up at 36 weeks post-baseline. Scores range from 0 - 54 with higher scores indicating worse depression.